Jeff Yass’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.69M Buy
240,700
+204,700
+569% +$3.92M ﹤0.01% 5016
2026
Q2
$656K Sell
36,000
-22,700
-39% -$337K ﹤0.01% 9272
2026
Q1
$834K Buy
58,700
+7,800
+15% +$100K ﹤0.01% 8373
2025
Q4
$527K Buy
+50,900
New +$459K ﹤0.01% 8664
2025
Q3
– Sell
-171,100
Closed -$1.29M – 12527
2025
Q2
$1.29M Buy
+171,100
New +$1.37M ﹤0.01% 6795
2023
Q4
– Sell
-10,200
Closed -$92.3K – 12422
2023
Q3
$92.3K Sell
10,200
-23,000
-69% -$240K ﹤0.01% 10985
2023
Q2
$357K Buy
+33,200
New +$353K ﹤0.01% 9080

Other funds holding CGEM

Jeff Yass's CGEM Position: Q3 2026 in Review

Jeff Yass increased its Cullinan Therapeutics (CGEM) stake by 173% in Q3 2026, buying an estimated $867K and bringing the position to 71,351 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #7708.

Jeff Yass first reported a position in CGEM in Q4 2021 and has held it in 18 quarters since. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Jeff Yass held 71,351 shares of Cullinan Therapeutics worth $1.1M as of Q3 2026.
  • Jeff Yass bought 45,261 Cullinan Therapeutics shares in Q3 2026, an estimated $867K.
  • Cullinan Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #7708 holding.
  • Jeff Yass first reported a position in Cullinan Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.